• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Fangdd Network Group Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket

    3/11/24 8:08:43 AM ET
    $ATXI
    $AUUD
    $BNED
    $BON
    Biotechnology: Pharmaceutical Preparations
    Health Care
    EDP Services
    Technology
    Get the next $ATXI alert in real time by email

    Shares of Fangdd Network Group Ltd. (NASDAQ:DUO) rose sharply in today’s pre-market trading after the company announced its 2024 strategic layout with plans to enter the real estate stock asset services sector.

    Fangdd Network Group shares jumped 78.3% to $1.08 in pre-market trading

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Kidpik Corp. (NASDAQ:PIK) gained 311% to $11.10 in pre-market trading. Kidpik recently announced a 1-for 5 reverse stock split.
    • Auddia Inc. (NASDAQ:AUUD) shares rose 50.1% to $4.64 in pre-market trading after falling over 8% on Friday.
    • Mesoblast Limited (NASDAQ:MESO) rose 28.4% to $2.76 in pre-market trading after the company said that the FDA supports an accelerated approval pathway for Rexlemestrocel-l in end-stage heart failure patients with a left ventricular assist device.
    • TC Biopharm (Holdings) Plc (NASDAQ:TCBP) gained 23.6% to $1.31 in pre-market trading.
    • Graphite Bio, Inc. (NASDAQ:GRPH) climbed 19.4% to $3.75 in pre-market trading. Graphite Bio declared a special dividend in connection with proposed merger with Lenz Therapeutics.
    • GDS Holdings Limited (NASDAQ:GDS) shares gained 17.7% to $7.54 in pre-market trading. Hillhouse Capital, Boyu Capital and CDH Investments are reportedly in advanced discussions to invest in the company’s data center business outside China, according to Bloomberg.
    • SRIVARU Holding Limited (NASDAQ:SVMH) shares gained 15.7% to $0.2730 in pre-market trading after declining 5% on Friday.
    • Kingsoft Cloud Holdings Limited (NASDAQ:KC) shares gained 13.7% to $3.06 in pre-market trading. Kingsoft Cloud is expected to report fourth-quarter financial results on March 20, 2024.
    • Bon Natural Life Limited (NASDAQ:BON) gained 13% to $0.4744 in pre-market trading after declining over 4% on Friday.

    Losers

    • Semilux International Ltd. (NASDAQ:SELX) fell 24.8% to $1.27 pre-market trading after jumping 69% on Friday.
    • Lytus Technologies Holdings PTV. Ltd. (NASDAQ:LYT) fell 20% to $6.40 in pre-market trading after declining 8% on Friday. Lytus Technologies, last week, announced the launch of Lytus Cloud.
    • Safe and Green Development Corporation (NASDAQ:SGD) shares dipped 20% to $0.9926 in pre-market trading. Safe and Green Development shares jumped 88% on Friday after the company announced financing for the Norman Berry Expansion in Atlanta, Georgia
    • Avenue Therapeutics, Inc. (NASDAQ:ATXI) fell 19% to $0.1555 pre-market trading after surging 10% on Friday.
    • Tenax Therapeutics, Inc. (NASDAQ:TENX) shares tumbled 18.5% to $3.31 in pre-market trading.
    • Barnes & Noble Education, Inc. (NYSE:BNED) dipped 18.5% to $0.74 in pre-market trading. Barnes & Noble Education recently rescheduled its third quarter fiscal year 2024 earnings release.
    • Psyence Biomedical Ltd. (NASDAQ:PBM) fell 17.1% to $1.75 in pre-market trading after jumping 66% on Friday. The company recently announced its subsidiary, Psyence Australia, received Human Research Ethics Committee approval to initiate its Phase IIb study.
    • CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) declined 15.2% to $3.35 in pre-market trading after jumping 28% on Friday. CERo Therapeutics recently announced the publication of preclinical research analyzing CER-1236 in targeting Acute Myelogenous Leukemia tumor cells from human patients.
    • Immuron Limited (NASDAQ:IMRN) shares tumbled 14.2% to $3.26 after dipping 16% on Friday.
    • Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares fell 13.8% to $8.60 in pre-market trading. Ocular Therapeutix is expected to report fourth-quarter financial results on March 11, 2024.

     

    Now Read This: Oracle, Casey's General Stores And 3 Stocks To Watch Heading Into Monday

     

    Get the next $ATXI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATXI
    $AUUD
    $BNED
    $BON

    CompanyDatePrice TargetRatingAnalyst
    Kingsoft Cloud Holdings Limited
    $KC
    2/11/2026$15.60Neutral → Buy
    Goldman
    Mesoblast Limited
    $MESO
    11/25/2025Hold → Buy
    Jefferies
    GDS Holdings Limited
    $GDS
    11/6/2025Outperform
    Macquarie
    Kingsoft Cloud Holdings Limited
    $KC
    9/16/2025$21.00Buy
    Deutsche Bank
    Ocular Therapeutix Inc.
    $OCUL
    9/15/2025$21.00Buy
    Chardan Capital Markets
    Kingsoft Cloud Holdings Limited
    $KC
    9/9/2025Neutral → Buy
    BofA Securities
    Tenax Therapeutics Inc.
    $TENX
    9/8/2025$20.00Overweight
    Piper Sandler
    GDS Holdings Limited
    $GDS
    8/12/2025$48.00Sector Perform → Outperform
    RBC Capital Mkts
    More analyst ratings

    $ATXI
    $AUUD
    $BNED
    $BON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ryoncil® Profits Underpinning Substantial Growth Pipeline

    NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (NASDAQ:MESO, ASX:MSB)), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended December 31, 2025 (H1 FY2026). FINANCIAL HIGHLIGHTS FOR H1 FY20261 Performance driven by successful commercial launch of Ryoncil® Total revenue of US$51.3 million (A$78.3 million),2 up from US$3.2 million.Successful U.S. commercial launch of Ryoncil® (remestemcel-L-rknd) generated gross sales of US$57.0 million and revenue of US$48.7 million after gross to net adjustment.Ryoncil® gross profit, excluding amortization, was US$44.2 million versus nil in

    2/26/26 7:42:54 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Immuron Reports HY26 Results and Strategic Reset

    Highlights (unaudited): Consistent Revenue Growth: Immuron is no longer just a "concept" company. Global H1 FY26 sales grew to AUD$4.2 million, with the U.S. market showing strong momentum (+17% YoY).Cash (AUD $10.0 million) to fund operating activities. Includes AUD $7.3 million (net) raised at an average price of A$0.0803 (IMRN USD$2.0923).Validated Platform: The "Hyper-Immune" platform is versatile. Beyond traveler's diarrhea (Travelan®), the company is moving into high-value clinical targets like C. diff (IMM-529)Partnerships: Immuron has taken a strategic decision to pursue partnerships to fund progress of Travelan® (IMM-124E) and IMM-529 clinical programs. IMM-124E: Eligible for end o

    2/25/26 6:00:00 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Auddia Highlights LT350 Business as Core AI Infrastructure Asset in Proposed Merger

    Proprietary technology turns any parking lot into a revenue generating datacenter delivering AI inference at the edge without absorbing parking spaces  Supports the fastest, most secure, and lowest cost inference runs for the highest paying customers handling the most sensitive data LT350 accounts for approximately 50% of McCarthy Finney's $250 million DCF valuation BOULDER, Colo., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Auddia Inc. (NASDAQ:AUUD) ("Auddia" or the "Company"), today announced a comprehensive strategic overview of LT350, a distributed AI compute business engineered to address two of the most urgent constraints in the AI infrastructure market: GPU underutilization and grid-const

    2/25/26 6:00:00 AM ET
    $AUUD
    EDP Services
    Technology

    $ATXI
    $AUUD
    $BNED
    $BON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lindstrom Richard L Md bought $461,354 worth of shares (60,229 units at $7.66), increasing direct ownership by 32% to 246,933 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/24/26 6:13:03 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rich Stuart bought $50,792 worth of shares (5,000 units at $10.16), increasing direct ownership by 90% to 5,266 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/10/25 6:48:57 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rich Stuart bought $45,622 worth of shares (5,000 units at $9.12), increasing direct ownership by 940% to 2,766 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/5/25 5:46:32 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXI
    $AUUD
    $BNED
    $BON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Dugel Pravin sold $166,064 worth of shares (20,056 units at $8.28), decreasing direct ownership by 0.66% to 3,013,022 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/25/26 6:20:23 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Kaiser Peter sold $23,267 worth of shares (2,810 units at $8.28), decreasing direct ownership by 1% to 269,108 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/25/26 6:19:11 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Heier Jeffrey S. sold $25,312 worth of shares (3,057 units at $8.28), decreasing direct ownership by 0.94% to 323,368 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/25/26 6:18:30 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXI
    $AUUD
    $BNED
    $BON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Kingsoft Cloud upgraded by Goldman with a new price target

    Goldman upgraded Kingsoft Cloud from Neutral to Buy and set a new price target of $15.60

    2/11/26 7:42:03 AM ET
    $KC
    Computer Software: Prepackaged Software
    Technology

    Mesoblast upgraded by Jefferies

    Jefferies upgraded Mesoblast from Hold to Buy

    11/25/25 8:34:05 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Macquarie initiated coverage on GDS Holdings

    Macquarie initiated coverage of GDS Holdings with a rating of Outperform

    11/6/25 8:38:06 AM ET
    $GDS
    Computer Software: Programming Data Processing
    Technology

    $ATXI
    $AUUD
    $BNED
    $BON
    SEC Filings

    View All

    SEC Form 6-K filed by Psyence Biomedical Ltd.

    6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

    3/2/26 7:07:39 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Kingsoft Cloud Holdings Limited

    6-K - Kingsoft Cloud Holdings Ltd (0001795589) (Filer)

    3/2/26 6:03:13 AM ET
    $KC
    Computer Software: Prepackaged Software
    Technology

    SEC Form 6-K filed by Immuron Limited

    6-K - Immuron Ltd (0001660046) (Filer)

    2/27/26 9:58:50 PM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXI
    $AUUD
    $BNED
    $BON
    Leadership Updates

    Live Leadership Updates

    View All

    Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders

    NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the voting results from its Annual and Special Meeting of Shareholders (the "Meeting"), held at 9:00 a.m. Eastern Time on February 12, 2026. Shareholders voted in favour of all matters of business presented at the Meeting, including the election of directors, the appointment of auditors and the approval of share consolidation authority for the board of directors (the "Board"). All director nominees listed in the Company's management informat

    2/17/26 9:15:00 AM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company's Board of Directors. "Eric's decades of financial, transactional and operational experience will make an immediate impact to CERo's board of directors," said Chris Ehrlich, Company Chairman and Chief Executive Officer. "Furthermore, his expertise in capital raising, M&A, and business development will be an impactful addition at this stage of our development." Mr. Francois is an executive with over 25

    2/17/26 8:00:00 AM ET
    $CERO
    $CRVO
    $SCYX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer

    Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while at Regeneron Most recently served as Chief Marketing Officer, Global Ophthalmology at Merck BEDFORD, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that David W. Robinson has agreed to join the Company as Global Chief Commercial Officer. The appointment of Mr. Robinson, a proven commercial leader with a history of launching category-defining therapies, strategically positions Ocular for success

    1/21/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXI
    $AUUD
    $BNED
    $BON
    Financials

    Live finance-specific insights

    View All

    Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations

    Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET) Company to host an investor webcast on Monday, March 2, 2026, at 7:30 AM ET to discuss the Macula Society presentations BEDFORD, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will present detailed results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), at the 49th Macula Soc

    2/23/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD

    First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment Superiority primary endpoint met with 74.1% of subjects in the AXPAXLI™ arm maintaining vision at Week 36, a 17.5% risk difference (p=0.0006), compared to aflibercept (2 mg) arm 65.9% of subjects treated with AXPAXLI maintained vision at Week 52, a 21.1% risk difference (p<0.0001), compared to aflibercept (2 mg) arm Rescue-free rates in the AXPAXLI arm were 80.6%, 74.7%, and 68.8% at Weeks 24, 36, and 52 55.9% of subjects treated with AXPAXLI maintained CSFT within 30 μm from baseline at Week 36, a 17.1% risk difference (nominal p=0.0

    2/17/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

    SOL-1 Phase 3 superiority trial results remain masked to date SOL-1 data expected to be presented at the 49th Macula Society Annual Meeting Ocular plans to submit NDA for AXPAXLI™ in wet AMD based on SOL-1 52 Week data, pending positive results and planned FDA interactions Completed randomization of 631 subjects in SOL-R Phase 3 non-inferiority trial in December 2025; timing of topline results accelerated and now anticipated in 1Q 2027 HELIOS-3 Phase 3 trial in diabetic retinopathy underway Cash balance of $737.1 million as of December 31, 2025, with expected runway into 2028 BEDFORD, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocula

    2/5/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATXI
    $AUUD
    $BNED
    $BON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fangdd Network Group Ltd.

    SC 13G - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:26:40 PM ET
    $DUO
    Real Estate
    Finance

    Amendment: SEC Form SC 13G/A filed by Fangdd Network Group Ltd.

    SC 13G/A - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:24:27 PM ET
    $DUO
    Real Estate
    Finance

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care